Saturday 17 October 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.5% and free cash flow fell 32.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.41
0.53
−5.33%
Follow INKT
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — | — | — | — |
P/S ratio |
— | 0.00 | — | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | (238.90) | — | — | — | — | — | — |
P/Operating CF |
— | (83.09) | — | — | — | — | — | — |
P/B ratio |
— | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
— | 0.00 | — | — | — | — | — | — |
EV/Sales |
— | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
— | (25.97) | — | — | — | — | — | — |
EV/FCF |
— | (25.47) | — | — | — | — | — | — |
Quick Ratio |
— | 0.04 | 0.19 | 2.36 | 1.55 | 0.30 | 0.66 | 1.03 |
Current Ratio |
— | 0.12 | 0.29 | 2.41 | 1.61 | 0.32 | 0.72 | 1.06 |
Net Debt/EBITDA |
— | (1.19) | (2.82) | 1.38 | 0.64 | 0.15 | (0.03) | 1.07 |
Debt/Assets |
0.00% | 2,046.79% | 962.07% | 0.00% | 0.00% | 0.00% | 86.08% | 0.00% |
Debt/Equity |
— | (0.74) | (0.81) | 0.00 | 0.00 | 0.00 | (0.25) | 0.00 |
Asset Turnover |
— | 1.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.63 | 0.51 | 0.42 | 0.67 | 0.70 | 0.89 | 0.47 |
Capex/Depreciation |
— | (11.59) | (1.73) | (3.19) | (2.05) | (0.36) | 0.00 | 0.00 |
Interest Coverage |
— | (14.28) | (6.00) | (11.66) | 122.18 | — | — | — |
| — | 52.77% | 36.00% | 200.76% | (239.49%) | 243.36% | 57.30% | 73.90% | |
| — | (3,636.98%) | (553.84%) | (134.89%) | (90.71%) | (172.59%) | (209.96%) | (125.20%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 389.56% | 167.98% | (127.07%) | (318.50%) | 327.84% | 870.51% | (1,034.81%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
— | 2,850.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 555.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 31.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.27) | — | — | — | — | — | — |
Graham Number |
— | 0.00 | — | — | — | — | — | — |
Earnings Yield |
— | (8.47%) | — | — | — | — | — | — |
Free Cash Flow Yield |
— | (4.51%) | — | — | — | — | — | — |
Revenue per Share |
— | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (6.21) | (3.46) | (4.93) | (5.60) | (4.59) | (2.53) | (1.39) |
Capex per Share |
— | (0.18) | (0.04) | (0.10) | (0.07) | (0.02) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (6.39) | (3.50) | (5.02) | (5.68) | (4.61) | (2.53) | (1.39) |
Cash per Share |
— | 0.12 | 1.12 | 14.94 | 5.83 | 0.98 | 1.21 | 3.13 |
Shareholders Equity per Share |
— | (15.10) | (22.35) | 9.14 | (0.12) | (5.25) | (5.19) | (3.33) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (15.10) | (22.35) | 9.14 | (0.12) | (5.25) | (5.19) | (3.33) |
Free Cash Flow |
— | (15.37) | (8.43) | (13.08) | (19.12) | (15.84) | (9.56) | (5.93) |
Working Capital |
— | (6.50) | (10.13) | 23.17 | 7.72 | (7.80) | (1.97) | 0.82 |
Capital Expenditures |
— | (0.43) | (0.10) | (0.25) | (0.25) | (0.07) | — | — |
Net Current Asset Value |
— | (36.72) | (54.33) | 23.17 | (1.47) | (19.01) | (20.32) | (14.62) |
EV/EBIT |
— | 0.00 | — | — | — | — | — | — |
Capex to Sales |
— | 0.62 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
— | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.09 | 0.12 | 0.13 | 0.11 | 0.21 | 0.29 | 0.46 |
Cash ROIC |
— | 166.27% | 114.59% | (20.87%) | (99.39%) | 107.81% | 94.76% | 683.10% |
Accounts Receivable Turnover |
— | 1.77 | 0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.39 | 0.39 | 0.14 | — | — | — | — |
Average Payables |
— | 2.80 | 2.80 | 3.07 | 4.41 | 4.87 | 3.32 | 3.08 |
Average Assets |
— | 0.65 | 2.93 | 22.40 | 30.86 | 13.01 | 5.14 | 9.98 |
Average Common Equity |
— | (45.10) | (45.10) | (15.05) | 11.69 | (9.23) | (18.82) | (16.91) |
Columns are period end dates